{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:59:54Z","timestamp":1787702394191,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.pcad.2019.11.005","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T11:28:27Z","timestamp":1573644507000},"page":"375-383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["The 2018 AHA\/ACC\/Multi-Society Cholesterol guidelines: Looking at past, present and future"],"prefix":"10.1016","volume":"62","author":[{"given":"Neil J.","family":"Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Grundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.pcad.2019.11.005_bb0005","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrcardio.2011.158","article-title":"Can we dramatically reduce the incidence of coronary heart disease?","volume":"8","author":"Domanski","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.pcad.2019.11.005_bb0010","doi-asserted-by":"crossref","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of triglyceride-Lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019 Jan 29;321(4):364\u2013373.","DOI":"10.1001\/jama.2018.20045"},{"issue":"2","key":"10.1016\/j.pcad.2019.11.005_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1373\/clinchem.2018.298026","article-title":"Hyperlipoproteinemia: the forgotten, disregarded, neglected, overlooked, ignored but highly atherogenic, and highly treatable dyslipoproteinemia","volume":"65","author":"Sniderman","year":"2019","journal-title":"Clin Chem"},{"key":"10.1016\/j.pcad.2019.11.005_bb0020","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ."},{"key":"10.1016\/j.pcad.2019.11.005_bb0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.pcad.2019.11.005_bb0030","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/eurheartj\/ehu208","article-title":"Mendelian randomization studies in coronary artery disease","volume":"35","author":"Jansen","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2019.11.005_bb0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"I. Reduction in incidence of coronary heart disease","volume":"251","author":"The Lipid Research Clinics Coronary Primary Prevention Trial Results","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2019.11.005_bb0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archinte.1988.00380010040006","article-title":"Report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults","volume":"148","author":"National Cholesterol Education Program","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pcad.2019.11.005_bb0045","doi-asserted-by":"crossref","unstructured":"Summary of the second report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA. 1993 Jun 16;269(23):3015\u201323.","DOI":"10.1001\/jama.1993.03500230097036"},{"key":"10.1016\/j.pcad.2019.11.005_bb0050","first-page":"3143","volume":"106","author":"Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","year":"2002","journal-title":"Final Report Circulation"},{"issue":"3","key":"10.1016\/j.pcad.2019.11.005_bb0055","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacc.2004.07.001","article-title":"Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"44","author":"Grundy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.11.005_bb0060","doi-asserted-by":"crossref","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014;63:2889\u2013934.","DOI":"10.1016\/j.jacc.2013.11.002"},{"key":"10.1016\/j.pcad.2019.11.005_bb0065","series-title":"ed, Mancher M, ed, Wolman DM, ed, Greenfield S, ed, Steinberg E, ed. Clinical practice guidelines we can trust","author":"Graham","year":"2011"},{"issue":"3","key":"10.1016\/j.pcad.2019.11.005_bb0070","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.amjcard.2015.04.062","article-title":"Familial hypercholesterolemia and the 2013 American College of Cardiology\/American Heart Association guidelines: myths, oversimplification, and misinterpretation versus facts","volume":"116","author":"Knowles","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2019.11.005_bb0075","first-page":"291","article-title":"Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S","volume":"163","author":"Downs","year":"2015","journal-title":"Department of Defense clinical practice guideline Ann Intern Med"},{"issue":"19","key":"10.1016\/j.pcad.2019.11.005_bb0080","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2016.15450","article-title":"et al; US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement","volume":"316","author":"Bibbins-Domingo","year":"2016","journal-title":"JAMA."},{"issue":"15","key":"10.1016\/j.pcad.2019.11.005_bb0085","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jama.2017.3416","article-title":"Comparison of recommended eligibility for primary prevention statin therapy based on the US preventive services task force recommendations vs the ACC\/AHA guidelines","volume":"317","author":"Pagidipati","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.pcad.2019.11.005_bb0090","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-e1143.","DOI":"10.1161\/CIR.0000000000000624"},{"issue":"3","key":"10.1016\/j.pcad.2019.11.005_bb0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2019.11.005_bb0100","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2019.11.005_bb0105","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pcad.2019.11.005_bb0110","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY OUTCOMES committees and investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pcad.2019.11.005_bb0115","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and Ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.11.005_bb0120","series-title":"Schwartz GG","author":"Roe","year":"2019"},{"issue":"10","key":"10.1016\/j.pcad.2019.11.005_bb0125","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2019.11.005_bb0130","doi-asserted-by":"crossref","unstructured":"Mahan CA, McGill HC, Gidding SS, Malcom GT, Newman WP, Tracy RE, Strong JP; Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. PDAY risk score predicts advanced coronary artery atherosclerosis in middle-aged persons as well as youth. Atherosclerosis. 2007 Feb;190(2):370\u20137. Epub 2006 Mar 10.","DOI":"10.1016\/j.atherosclerosis.2006.02.008"},{"key":"10.1016\/j.pcad.2019.11.005_bb0135","series-title":"Eckel RH","author":"Chait","year":"2019"},{"issue":"5","key":"10.1016\/j.pcad.2019.11.005_bb0140","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacl.2012.08.002","article-title":"Severe hypertriglyceridemia","volume":"6","author":"Brown","year":"2012","journal-title":"J Clin Lipidol"},{"issue":"9784","key":"10.1016\/j.pcad.2019.11.005_bb0145","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.pcad.2019.11.005_bb0150","doi-asserted-by":"crossref","unstructured":"Stone NJ, Levy, RI, Fredrickson DS, Verter,J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circ1974; 49: 476\u2013488.","DOI":"10.1161\/01.CIR.49.3.476"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062019301392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:16:28Z","timestamp":1758500188000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062019301392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0033062019301392"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2019.11.005","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 2018 AHA\/ACC\/Multi-Society Cholesterol guidelines: Looking at past, present and future","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2019.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}